hi to all

does anyone know when medpharma will be listed on aim,and at what price range?
thanks.

petralva

Well according to their web site this month why not Email them and ask?
Sorry if you already knew this but why the interest?

Click here for link to web site

petralva/ Martini,

here's the link; http://www.urodoc.co.uk/medpharma/

And here's the info your require, straight from their website;
-----------------------------------------------------------------------------
Latest News
Medpharma plc - Intention to Float on the Alternative Investment Market of the London Stock Exchange

Medpharma, a UK based biotechnology company focusing on the treatment of urological disorders, announces its intention to seek admission for its shares to trade on AIM by way of a Placing

Three areas of initial focus for Medpharma are sexual dysfunction, incontinence and prostate cancer. The most advanced product is for premature ejaculation, while additional product areas include female sexual dysfunction and quality and strength of orgasm

Medpharma is seeking to raise 8 million net

Market capitalisation is expected to be in the region of 33 million

Strong management team and scientific advisory board

Established record for generating revenues

Medpharma minimises risk though its strategy of in-licensing drugs from big pharmaceutical companies, taking them through Phased II proof of concept trials and then out-licensing or partnering them for Phase III studies, regulatory approval and marketing

Has a robust product pipeline - 6 products - 4 in Phase II clinical trials with 2 devices in validation.

2 advanced products approaching commercialisation.

Grant Thornton is the nominated adviser and Hoodless Brennan is the appointed broker

Medpharma is focused on exploiting the clinical benefits of novel combinations of established pharmaceuticals and the development of delivery systems and devices for the diagnosis, treatment and management of urological disorders.

Urology is one of the fastest growing sectors of the pharmaceutical market with a market value currently estimated at $7-8 billion excluding cancer treatments and indirect healthcare costs. The Directors expect this to increase significantly in the short to medium term as new drugs become available to treat a wider range of urological disorders. Further, the Directors believe that, spurred by an ageing population, increasing wealth and lifestyle expectations in the developed world and greater patient awareness, this market sector will continue to have significant and sustained growth in the longer term. It is estimated that in the USA alone, over 11 million people suffer from a severe urological disorder.

Medpharma's strategy is to create and protect intellectual property by extending the use of established licensed drugs for application within the field of urology. Additionally, as pharmaceutical companies are increasingly looking to outsource R&D projects as part of their strategy to obtain new products and or new uses for existing products, quickly and at lower risk, Medpharma's approach is to collaborate with these companies to add value to their products through the expertise of its team.
Three areas of initial focus for Medpharma are sexual dysfunction, incontinence and prostate cancer. The most advanced product is for premature ejaculation, while additional product areas include female sexual dysfunction and quality and strength of orgasm.

In three and a half years since it was founded Medpharma has developed a strong product pipeline including four drugs in Phase II clinical development and two devices in validation. Two of these products are currently approaching commercialisation.


Timetable

Pathfinder Prospectus Published - April 2003
Impact Day - May 2003
First Day Dealings - May 2003

On the plans for flotation, Neil Stafford, Chairman said "I am extremely pleased with Medpharma's progress over the last three and half years. Gaining admission to AIM will raise awareness of the Company's business and provide funding which should take the Company through to profitability."